Role of nitric oxide and related molecules in schizophrenia pathogenesis: Biochemical, genetic and clinical aspects

Frontiers in Physiology

Volumn 6, Issue MAY, 2015, Pages

  Nasyrova, Regina F ^a   Ivashchenko, Dmitriy V ^a   Ivanov, Mikhail V ^a   Neznanov, Nikolay G ^a  

^a Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

Author keywords

Genetics; Nitric oxide; Nitric oxide synthase; NO; NOS; Oxidative stress; Pathogenesis; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANTIOXIDANT; CATALASE; CLOZAPINE; FREE RADICAL; GLUTAMIC ACID; GLUTATHIONE PEROXIDASE; GLYCINE; HALOPERIDOL; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSINE; MINOCYCLINE; NEUROLEPTIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PLACEBO; SUPEROXIDE DISMUTASE; TAURINE;

AUTOPSY; BODY FLUID; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CLINICAL FEATURE; CORPUS STRIATUM; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MEDIATOR RELEASE; NEGATIVE SYNDROME; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PEROXIDATION; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84930628733     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00139     Document Type: Review

References (214)

1. Akpinar, A., Yaman, G. B., Demirdas, A., and Onal, S. (2013). Possible role of adrenomedullin and nitric oxide in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 46, 120-125. doi: 10.1016/j.pnpbp.2013.07.003.
2. Akyol, O., Zoroglu, S. S., Armutcu, F., Sahin, S., and Gurel, A. (2004). Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18, 377-390.
3. Albayrak, Y., Ünsal, C., Beyazyüz, M., Ünal, A., and Kuloğlu, M. (2013). Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 144-149. doi: 10.1016/j.pnpbp.2013.04.020.
4. Antunes, F., Nunes, C., Laranjinha, J., and Cadenas, E. (2005). Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology 208, 207-212. doi: 10.1016/j.tox.2004.11.033.
5. Archer, S. (1993). Measurement of nitric oxide in biological models. FASEB J. 7, 349-360.
6. Ataya, B., Tzeng, E., and Zuckerbraun, B. S. (2011). Nitrite-generated nitric oxide to protect against intimal hyperplasia formation. Trends Cardiovasc. Med. 21, 157-162. doi: 10.1016/j.tcm.2012.05.002.
7. Austin, S. A., Santhanam, A. V., Hinton, D. J., Choi, D. S., and Katusic, Z. S. (2013). Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J. Neurochem. 127, 691-700. doi: 10.1111/jnc.12334.
8. Averbukh, M. L., Kas'ko, A. F., Nikolenko, E. S., and Rybas, I. I. (1966). On the diagnostic significance of Black's reaction in psychiatric patients. Lab. Delo 5, 289-291.
9. Baba, H., Suzuki, T., Arai, H., and Emson, P. C. (2004). Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15, 677-680. doi: 10.1097/00001756-200403220-00020.
10. Babicová, A., Havlínová, Z., Hroch, M., Rezáèová, M., Pejchal, J., Vávrová, J., et al. (2013). In vivo study of radioprotective effect of NO-synthase inhibitors and acetyl-L-carnitine. Physiol. Res. 62, 701-710.
11. Bauer, I. E., Pascoe, M. C., Wollenhaupt-Aguiar, B., Kapczinski, F., and Soares, J. C. (2014). Inflammatory mediators of cognitive impairment in bipolar disorder. J. Psychiatr. Res. 56, 18-27. doi: 10.1016/j.jpsychires.2014.04.017.
12. Ben Othmen, L., Mechri, A., Fendri, C., Bost, M., Chazot, G., Gaha, L., et al. (2008). Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 155-159. doi: 10.1016/j.pnpbp.2007.08.003.
13. Ben-Shachar, D., and Laifenfeld, D. (2004). Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59, 273-296. doi: 10.1016/S0074-7742(04)59011-6.
14. Berg, D., Youdim, M. B., and Riederer, P. (2004). Redox imbalance. Cell Tissue Res. 318, 201-213. doi: 10.1007/s00441-004-0976-5.
15. Bergink, V., Gibney, S. M., and Drexhage, H. A. (2014). Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol. Psychiatry 75, 324-331. doi: 10.1016/j.biopsych.2013.09.037.
16. Bernstein, H. G., Bogerts, B., and Keilhoff, G. (2005a). The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 78, 69-86 doi: 10.1016/j.schres.2005.05.019.
17. Bernstein, H. G., Heinemann, A., Krell, D., Dobrowolny, H., Bielau, H., Keilhoff, G., et al. (2005b). Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. Cell. Mol. Biol. 51, 279-284.
18. Bernstein, H. G., Heinemann, A., Steiner, J., and Bogerts, B. (2010). Schizophrenia, sleep disturbances and the suprachiasmatic nucleus: reduced nitric oxide synthase may matter. Med. Hypotheses 74, 397-398. doi: 10.1016/j.mehy.2009.08.026.
19. Bernstein, H. G., Jirikowski, G. F., Heinemann, A., Baumann, B., Hornstein, C., Danos, P., et al. (2000). Low and infrequent expression of nitric oxide synthase/NADPH-diaphorase in neurons of the human supraoptic nucleus: a histochemical study. J. Chem. Neuroanat. 20, 177-183. doi: 10.1016/S0891-0618(00)00087-9.
20. Bernstein, H. G., Keilhoff, G., Steiner, J., Dobrowolny, H., and Bogerts, B. (2011). Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS Neurol. Disord. Drug Targets 10, 792-807. doi: 10.2174/187152711798072392.
21. Bernstein, H. G., Krell, D., Braunewell, K. H., Baumann, B., Gundelfinger, E. D., Diekmann, S., et al. (2001). Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J. Neurocytol. 30, 661-670. doi: 10.1023/A:1016520932139.
22. Bernstein, H. G., Stanarius, A., Baumann, B., Henning, H., Krell, D., Danos, P., et al. (1998). Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83, 867-875. doi: 10.1016/S0306-4522(97)00461-2.
23. Bitanihirwe, B. K., and Woo, T. U. (2011). Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 35, 878-893. doi: 10.1016/j.neubiorev.2010.10.008.
24. Blaise, G. A., Gauvin, D., Gangal, M., and Authier, S. (2005). Nitric oxide, cell signaling and cell death. Toxicology 208, 177-192. doi: 10.1016/j.tox.2004.11.032.
25. Blasko, J., Fabianova, K., Martoncikova, M., Sopkova, D., and Racekova, E. (2013). Immunohistochemical evidence for the presence of synaptic connections of nitrergic neurons in the rat rostral migratory stream. Cell. Mol. Neurobiol. 33, 753-757. doi: 10.1007/s10571-013-9956-1.
26. Blum-Degen, D., Heinemann, T., Lan, J., Pedersen, V., Leblhuber, F., Paulus, W., et al. (1999). Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. Brain Res. 834, 128-135. doi: 10.1016/S0006-8993(99)01444-4.
27. Boehning, D., and Snyder, S. H. (2003). Novel neural modulators. Annu. Rev. Neurosci. 26, 105-131. doi: 10.1146/annurev.neuro.26.041002.131047.
28. Bringas, M. E., Morales-Medina, J. C., Flores-Vivaldo, Y., Negrete-Diaz, J. V., Aguilar-Alonso, P., León-Chávez, B. A., et al. (2012). Clozapine administration reverses behavioral, neuronal, and nitric oxide disturbances in the neonatal ventral hippocampus rat. Neuropharmacology 62, 1848-1857. doi: 10.1016/j.neuropharm.2011.12.008.
29. Brown, A. S., and Derkits, E. J. (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167, 261-280. doi: 10.1176/appi.ajp.2009.09030361.
30. Brzustowicz, L. M., Simone, J., Mohseni, P., Hayter, J. E., Hodgkinson, K. A., Chow, E. W., et al. (2004). Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am. J. Hum. Genet. 74, 1057-1063. doi: 10.1086/420774.
31. Bul'ba, P. A., Kas'ko, A. F., Averbukh, M. L., and Nikolenko, E. S. (1968). Peculiarities of the Black reaction and white phenomenon in mental patients. 2. Lab. Delo 6, 350-352.
32. Carreira, B. P., Morte, M. I., Lourenço, A. S., Santos, A. I., Inácio, A., Ambrósio, A. F., et al. (2013). Differential contribution of the guanylyl cyclase-cyclic GMP-protein kinase G pathway to the proliferation of neural stem cells stimulated by nitric oxide. Neurosignals 21, 1-13. doi: 10.1159/000332811.
33. Chen, J., Tu, Y., Moon, C., Matarazzo, V., Palmer, A. M., and Ronnett, G. V. (2004). The localization of neuronal nitric oxide synthase may influence its role in neuronal precursor proliferation and synaptic maintenance. Dev. Biol. 269, 165-182. doi: 10.1016/j.ydbio.2004.01.024.
34. Chiueh, C. C. (1999). Neuroprotective properties of nitric oxide. Ann. N.Y. Acad. Sci. 890, 301-311. doi: 10.1111/j.1749-6632.1999.tb08007.x.
35. Ciancarelli, I., De Amicis, D., Di Massimo, C., Di Scanno, C., Pistarini, C., D'Orazio, N., et al. (2014). Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients. Biomarkers 19, 452-456. doi: 10.3109/1354750X.2014.935955.
36. Clarke, M. C., Tanskanen, A., Huttunen, M., Leon, D. A., Murray, R. M., Jones, P. B., et al. (2011). Increased risk of schizophrenia from additive interaction between infant motor developmental delay and obstetric complications: evidence from a population-based longitudinal study. Am. J. Psychiatry 168, 1295-1302. doi: 10.1176/appi.ajp.2011.11010011.
37. Connor, C. M., Crawford, B. C., and Akbarian, S. (2011). White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosci. 29, 325-334. doi: 10.1016/j.ijdevneu.2010.07.236.
38. Contestabile, A., Monti, B., and Polazzi, E. (2012). Neuronal-glial interactions define the role of nitric oxide in neural functional processes. Curr. Neuropharmacol. 10, 303-310. doi: 10.2174/157015912804499465.
39. Cooke, R. M., Mistry, R., Challiss, R. A., and Straub, V. A. (2013). Nitric oxide synthesis and cGMP production is important for neurite growth and synapse remodeling after axotomy. J. Neurosci. 33, 5626-5637. doi: 10.1523/JNEUROSCI.3659-12.2013.
40. Creese, I., Burt, D. R., and Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483. doi: 10.1126/science.3854.
41. Cui, H., Nishiguchi, N., Yanagi, M., Fukutake, M., Mouri, K., Kitamura, N., et al. (2010). A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr. Res. 121, 172-178. doi: 10.1016/j.schres.2010.05.003.
42. Dadheech, G., Mishra, S., Gautam, S., and Sharma, P. (2008). Evaluation of antioxidant deficit in schizophrenia. Indian J. Psychiatry 50, 16-20. doi: 10.4103/0019-5545.39753.
43. Davies, K. J. (1995). Oxidative stress: the paradox of aerobic life. Biochem. Soc. Symp. 61, 1-31.
44. Davis, K. L., Kahn, R. S., Ko, G., and Davidson, M. (1991). Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486. doi: 10.1176/ajp.148.11.1474.
45. Dec, A. M., Kohlhaas, K. L., Nelson, C. L., Hoque, K. E., Leilabadi, S. N., Folk, J., et al. (2014). Impact of neonatal NOS-1 inhibitor exposure on neurobehavioural measures and prefrontal-temporolimbic integration in the rat nucleus accumbens. Int. J. Neuropsychopharmacol. 17, 275-287. doi: 10.1017/S1461145713000990.
46. Delorme, R., Betancur, C., Scheid, I., Anckarsäter, H., Chaste, P., Jamain, S., et al. (2010). Mutation screening of NOS1AP gene in a large sample of psychiatric patients and controls. BMC Med. Genet. 11:108. doi: 10.1186/1471-2350-11-108.
47. de Witte, L., Tomasik, J., Schwarz, E., Guest, P. C., Rahmoune, H., Kahn, R. S., et al. (2014). Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 154, 23-29. doi: 10.1016/j.schres.2014.02.005.
48. Dickson, H., Laurens, K. R., Cullen, A. E., and Hodgins, S. (2012). Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol. Med. 42, 743-755. doi: 10.1017/S0033291711001693.
49. Dietrich-Muszalska, A., and Kontek, B. (2010). Lipid peroxidation in patients with schizophrenia. Psychiatry Clin. Neurosci. 64, 469-475. doi: 10.1111/j.1440-1819.2010.02132.x.
50. Dietrich-Muszalska, A., Kontek, B., and Rabe-Jabłñska, J. (2011). Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 63, 197-201. doi: 10.1159/000321623.
51. Dietrich-Muszalska, A., and Kwiatkowska, A. (2014). Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia. Neuropsychiatr. Dis. Treat. 10, 703-709. doi: 10.2147/NDT.S60034.
52. Dietrich-Muszalska, A., and Olas, B. (2009). Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 10, 27-33. doi: 10.1080/15622970701361263.
53. Diodati, J. G., Dakak, N., Gilligan, D. M., and Quyyumi, A. A. (1998). Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98, 17-24. doi: 10.1161/01.CIR.98.1.17.
54. Donohoe, G., Walters, J., Morris, D. W., Quinn, E. M., Judge, R., Norton, N., et al. (2009). Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Arch. Gen. Psychiatry 66, 1045-1054. doi: 10.1001/archgenpsychiatry.2009.139.
55. Doyle, C. A., and Slater, P. (1995). Application of [3H]L-N(G)-nitro-arginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci. Lett. 202, 49-52. doi: 10.1016/0304-3940(95)12196-X.
56. Dracheva, S., McGurk, S. R., and Haroutunian, V. (2005). mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 79, 868-878. doi: 10.1002/jnr.20423.
57. Duan, J., Li, W., Yuan, D., Sah, B., Yan, Y., and Gu, H. (2012). Nitric oxide signaling modulates cholinergic synaptic input to projection neurons in Drosophila antennal lobes. Neuroscience 219, 1-9. doi: 10.1016/j.neuroscience.2012.05.068.
58. Eastwood, S. L., and Harrison, P. J. (2003). Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol. Psychiatry 8, 769, 821-831. doi: 10.1038/sj.mp.4001371.
59. Eaton, W. W., Thara, R., Federman, B., Melton, B., and Liang, K. Y. (1995). Structure and course of positive and negative symptoms in schizophrenia. Arch. Gen. Psychiatry 52, 127-134. doi: 10.1001/archpsyc.1995.03950140045005.
60. Endres, M., Laufs, U., Liao, J. K., and Moskowitz, M. A. (2004). Targeting eNOS for stroke protection. Trends Neurosci. 27, 283-289. doi: 10.1016/j.tins.2004.03.009.
61. Fatemi, S. H., Cuadra, A. E., El-Fakahany, E. E., Sidwell, R. W., and Thuras, P. (2000). Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 11, 1493-1496. doi: 10.1097/00001756-200005150-00026.
62. Finnerty, N. J., Bolger, F. B., Pålsson, E., and Lowry, J. P. (2013). An investigation of hypofrontality in an animal model of schizophrenia using real-time microelectrochemical sensors for glucose, oxygen, and nitric oxide. ACS Chem. Neurosci. 4, 825-831. doi: 10.1021/cn4000567.
63. Flatow, J., Buckley, P., and Miller, B. J. (2013). Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 74, 400-409. doi: 10.1016/j.biopsych.2013.03.018.
64. Fleming, I., and Busse, R. (2003). Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1-R12. doi: 10.1152/ajpregu.00323.2002.
65. Fritzen, S., Lauer, M., Schmitt, A., Töpner, T., Strobel, A., Lesch, K. P., et al. (2007). NO synthase-positive striatal interneurons are decreased in schizophrenia. Eur. Neuropsychopharmacol. 17, 595-599. doi: 10.1016/j.euroneuro.2006.12.004.
66. Furchgott, R. F., and Zawadzki, J. V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376. doi: 10.1038/288373a0.
67. Ghafourifar, P., and Cadenas, E. (2005). Mitochondrial nitric oxide synthase. Trends Pharmacol. Sci. 26, 190-195. doi: 10.1016/j.tips.2005.02.005.
68. Ghanizadeh, A., Dehbozorgi, S., Sigaroodi, M. O., and Rezaei, Z. (2014). Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat. Inflamm. Allergy Drug Discov. 8, 211-215. doi: 10.2174/1872213X08666141029123524.
69. Ghasemi, M., and Fatemi, A. (2014). Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases. Neurosci. Biobehav. Rev. 45, 168-182. doi: 10.1016/j.neubiorev.2014.06.002.
70. Gibbs, S. M. (2003). Regulation of neuronal proliferation and differentiation by nitric oxide. Mol. Neurobiol. 27, 107-120. doi: 10.1385/MN:27:2:107.
71. Gilca, M., Piriu, G., Gaman, L., Delia, C., Iosif, L., Atanasiu, V., et al. (2014). A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology. doi: 10.1007/s00213-014-3624-0.
72. Giraldi-Guimarães, A., Bittencourt-Navarrete, R. E., and Mendez-Otero, R. (2004). Expression of neuronal nitric oxide synthase in the developing superficial layers of the rat superior colliculus. Braz. J. Med. Biol. Res. 37, 869-877. doi: 10.1590/S0100-879X2004000600013.
73. Girouard, H., Wang, G., Gallo, E. F., Anrather, J., Zhou, P., Pickel, V. M., et al. (2009). NMDA receptor activation increases free radical production through nitric oxide and NOX2. J. Neurosci. 29, 2545-2552. doi: 10.1523/JNEUROSCI.0133-09.2009.
74. González-Forero, D., and Moreno-López, B. (2014). Retrograde response in axotomized motoneurons: nitric oxide as a key player in triggering reversion toward a dedifferentiated phenotype. Neuroscience 283, 138-165. doi: 10.1016/j.neuroscience.2014.08.021.
75. Gonzalez-Liencres, C., Tas, C., Brown, E. C., Erdin, S., Onur, E., Cubukcoglu, Z., et al. (2014). Oxidative stress in schizophrenia: a case¿control study on the effects on social cognition and neurocognition. BMC Psychiatry 14:268. doi: 10.1186/s12888-014-0268-x.
76. Graber, D. J., Snyder-Keller, A., Lawrence, D. A., and Turner, J. N. (2012). Neurodegeneration by activated microglia across a nanofiltration membrane. J. Biochem. Mol. Toxicol. 26, 45-53. doi: 10.1002/jbt.20384.
77. Gray, W. P., and Cheung, A. (2014). Nitric oxide regulation of adult neurogenesis. Vitam. Horm. 96, 59-77. doi: 10.1016/B978-0-12-800254-4.00004-0.
78. Gubert, C., Stertz, L., Pfaffenseller, B., Panizzutti, B. S., Rezin, G. T., Massuda, R., et al. (2013). Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J. Psychiatr. Res. 47, 1396-1402. doi: 10.1016/j.jpsychires.2013.06.018.
79. Gwathmey, T. M., Alzayadneh, E. M., Pendergrass, K. D., and Chappell, M. C. (2012). Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R518-R530. doi: 10.1152/ajpregu.00525.2011.
80. Haller, C. S., Padmanabhan, J. L., Lizano, P., Torous, J., and Keshavan, M. (2014). Recent advances in understanding schizophrenia. F1000Prime Rep. 6:57 doi: 10.12703/P6-57.
81. Halliwell, B. (2007). Biochemistry of oxidative stress. Biochem. Soc. Trans. 35(Pt 5), 1147-1150. doi: 10.1042/BST0351147.
82. Hara, H., Waeber, C., Huang, P. L., Fujii, M., Fishman, M. C., and Moskowitz, M. A. (1996). Brain distribution of nitric oxide synthase in neuronal or endothelial nitric oxide synthase mutant mice using [3H] L-NG-nitro-arginine autoradiography. Neuroscience 75, 881-890. doi: 10.1016/0306-4522(96)00313-2.
83. Hardy, J., and Gwinn-Hardy, K. (1998). Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079. doi: 10.1126/science.282.5391.1075.
84. Hart, S. J., Bizzell, J., McMahon, M. A., Gu, H., Perkins, D. O., and Belger, A. (2013). Altered fronto-limbic activity in children and adolescents with familial high risk for schizophrenia. Psychiatry Res. 212, 19-27. doi: 10.1016/j.pscychresns.2012.12.003.
85. Hoffer, A., Osmond, H., and Smythies, J. (1954). Schizophrenia; a new approach. II. Result of a year's research. J. Ment. Sci. 100, 29-45. doi: 10.1192/bjp.100.418.29.
86. Hölscher, C., and Rose, S. P. (1992). An inhibitor of nitric oxide synthesis prevents memory formation in the chick. Neurosci. Lett. 145, 165-167. doi: 10.1016/0304-3940(92)90012-V.
87. Hoque, K. E., Indorkar, R. P., Sammut, S., and West, A. R. (2010). Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity. Psychopharmacology 207, 571-581. doi: 10.1007/s00213-009-1687-0.
88. Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., et al. (2011). Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 16, 885-886. doi: 10.1038/mp.2011.20.
89. Howes, O. D., and Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 35, 549-562. doi: 10.1093/schbul/sbp006.
90. Hu, W., MacDonald, M. L., Elswick, D. E., and Sweet, R. A. (2014). The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann. N.Y. Acad. Sci. 1338, 38-57. doi: 10.1111/nyas.12547.
91. Hu, Y., and Zhu, D. Y. (2014). Hippocampus and nitric oxide. Vitam. Horm. 96, 127-160. doi: 10.1016/B978-0-12-800254-4.00006-4.
92. Jenkins, T. A. (2013). Perinatal complications and schizophrenia: involvement of the immune system. Front. Neurosci. 7:110. doi: 10.3389/fnins.2013.00110.
93. Jing, Y., Zhang, H., Wolff, A. R., Bilkey, D. K., and Liu, P. (2013). Altered arginine metabolism in the hippocampus and prefrontal cortex of maternal immune activation rat offspring. Schizophr. Res. 148, 151-156. doi: 10.1016/j.schres.2013.06.001.
94. Käkelä, J., Panula, J., Oinas, E., Hirvonen, N., Jääskeläinen, E., and Miettunen, J. (2014). Family history of psychosis and social, occupational and global outcome in schizophrenia: a meta-analysis. Acta Psychiatr. Scand. 130, 269-278. doi: 10.1111/acps.12317.
95. Kawakami, S., Ichikawa, M., Yokosuka, M., Tsukamura, H., and Maeda, K. (1998). Glial and neuronal localization of neuronal nitric oxide synthase immunoreactivity in the median eminence of female rats. Brain Res. 789, 322-326. doi: 10.1016/S0006-8993(97)01561-8.
96. Keshavan, M. S., Clementz, B. A., Pearlson, G. D., Sweeney, J. A., and Tamminga, C. A. (2013). Reimagining psychoses: an agnostic approach to diagnosis. Schizophr. Res. 146, 10-16. doi: 10.1016/j.schres.2013.02.022.
97. Khodaie-Ardakani, M. R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S. M., Modabbernia, A., et al. (2014). Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 215, 540-546. doi: 10.1016/j.psychres.2013.12.051.
98. Kirchner, L., Weitzdoerfer, R., Hoeger, H., Url, A., Schmidt, P., Engelmann, M., et al. (2004). Impaired cognitive performance in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements. Nitric Oxide 11, 316-330. doi: 10.1016/j.niox.2004.10.005.
99. Kiss, J. P., and Vizi, E. S. (2001). Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci. 24, 211-215. doi: 10.1016/S0166-2236(00)01745-8.
100. Knox, L. T., Jing, Y., Collie, N. D., Zhang, H., and Liu, P. (2014). Effects of acute phencyclidine administration on arginine metabolism in the hippocampus and prefrontal cortex in rats. Neuropharmacology 81, 195-205. doi: 10.1016/j.neuropharm.2014.02.004.
101. Kohen, R., and Nyska, A. (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 30, 620-650. doi: 10.1080/01926230290166724.
102. Kraus, M. M., and Prast, H. (2001). The nitric oxide system modulates the in vivo release of acetylcholine in the nucleus accumbens induced by stimulation of the hippocampal fornix/fimbria-projection. Eur. J. Neurosci. 14, 1105-1112. doi: 10.1046/j.0953-816x.2001.01735.x.
103. Kristofiková, Z., Kozmiková, I., Hovorková, P., Rícnỳ, J., Zach, P., Majer, E., et al. (2008). Lateralization of hippocampal nitric oxide mediator system in people with Alzheimer disease, multi-infarct dementia and schizophrenia. Neurochem. Int. 53, 118-125. doi: 10.1016/j.neuint.2008.06.009.
104. Kypreos, K. E., Zafirovic, S., Petropoulou, P. I., Bjelogrlic, P., Resanovic, I., Traish, A., et al. (2014). Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J. Cardiovasc. Pharmacol. Ther. 19, 256-268. doi: 10.1177/1074248413513499.
105. Lau, Y. S., Petroske, E., Meredith, G. E., and Wang, J. Q. (2003). Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology 45, 986-994. doi: 10.1016/S0028-3908(03)00314-9.
106. Lauer, M., Johannes, S., Fritzen, S., Senitz, D., Riederer, P., and Reif, A. (2005). Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiology 52, 111-117. doi: 10.1159/000087555.
107. Lazzaro, M., Bettegazzi, B., Barbariga, M., Codazzi, F., Zacchetti, D., and Alessio, M. (2014). Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia. J. Neuroinflammation 11, 164. doi: 10.1186/s12974-014-0164-9.
108. Lerouet, D., Beray-Berthat, V., Palmier, B., Plotkine, M., and Margaill, I. (2002). Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats. Brain Res. 958, 166-175. doi: 10.1016/S0006-8993(02)03685-5.
109. Lewis, D. A., Hashimoto, T., and Volk, D. W. (2005). Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312-324. doi: 10.1038/nrn1648.
110. Li, X. F., Zheng, Y. L., Xiu, M. H., Chen da, C., Kosten, T. R., and Zhang, X. Y. (2011). Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1064-1067. doi: 10.1016/j.pnpbp.2011.03.001.
111. Liou, Y. J., Tsai, S. J., Hong, C. J., and Liao, D. L. (2003). Association analysis for the CA repeat polymorphism of the neuronal nitric oxide synthase (NOS1) gene and schizophrenia. Schizophr. Res. 65, 57-59. doi: 10.1016/S0920-9964(02)00532-7.
112. Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., et al. (2014). Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr. Res. 153, 169-176. doi: 10.1016/j.schres.2014.01.011.
113. Lonart, G., Wang, J., and Johnson, K. M. (1992). Nitric oxide induces neurotransmitter release from hippocampal slices. Eur. J. Pharmacol. 220, 271-272. doi: 10.1016/0014-2999(92)90759-W.
114. Luo, C. X., Zhu, X. J., Zhou, Q. G., Wang, B., Wang, W., Cai, H. H., et al. (2007). Reduced neuronal nitric oxide synthase is involved in ischemia-induced hippocampal neurogenesis by up-regulating inducible nitric oxide synthase expression. J. Neurochem. 103, 1872-1882. doi: 10.1111/j.1471-4159.2007.04915.x.
115. Maia-de-Oliveira, J. P., Trzesniak, C., Oliveira, I. R., Kempton, M. J., Rezende, T. M., Iego, S., et al. (2012). Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis. Rev. Bras. Psiquiatr. 34(Suppl. 2), S149-S155. doi: 10.1016/j.rbp.2012.07.001.
116. Markovic, M., Miljkovic, D. J., and Trajkovic, V. (2003). Regulation of inducible nitric oxide synthase by cAMP-elevating phospho-diesterase inhibitors. Curr. Drug Targets Inflamm. Allergy 2, 63-79. doi: 10.2174/1568010033344471.
117. McConell, G. K., Bradley, S. J., Stephens, T. J., Canny, B. J., Kingwell, B. A., and Lee-Young, R. S. (2007). Skeletal muscle nNOS mu protein content is increased by exercise training in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R821-R828. doi: 10.1152/ajpregu.00796.2006.
118. McGrath, J., Saha, S., Chant, D., and Welham, J. (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67-76. doi: 10.1093/epirev/mxn001.
119. Miljevic, C., Nikolic, M., Nikolic-Kokic, A., Jones, D. R., Niketic, V., Lecic-Tosevski, D., et al. (2010). Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 303-307. doi: 10.1016/j.pnpbp.2009.11.024.
120. Miller, D. M., Buettner, G. R., and Aust, S. D. (1990). Transition metals as catalysts of "autoxidation" reactions. Free Radic. Biol. Med. 8, 95-108. doi: 10.1016/0891-5849(90)90148-C.
121. Morera, A. L., Intxausti, A., and Abreu-Gonzalez, P. (2009). Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research. World J. Biol. Psychiatry 10(4 Pt 2), 576-580. doi: 10.1080/15622970801901802.
122. Moylan, S., Berk, M., Dean, O. M., Samuni, Y., Williams, L. J., O'Neil, A., et al. (2014). Oxidative & nitrosative stress in depression: why so much stress? Neurosci. Biobehav. Rev. 45, 46-62. doi: 10.1016/j.neubiorev.2014.05.007.
123. Nel, A., and Harvey, B. H. (2003). Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav. Pharmacol. 14, 251-255. doi: 10.1097/00008877-200305000-00010.
124. Noack, H., Possel, H., Rethfeldt, C., Keilhoff, G., and Wolf, G. (1999). Peroxynitrite mediated damage and lowered superoxide tolerance in primary cortical glial cultures after induction of the inducible isoform of NOS. Glia 28, 13-24.
125. Northoff, G., Richter, A., Bermpohl, F., Grimm, S., Martin, E., Marcar, V. L., et al. (2005). NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr. Res. 72, 235-248. doi: 10.1016/j.schres.2004.04.009.
126. O'Donoghue, T., Morris, D. W., Fahey, C., Da Costa, A., Foxe, J. J., Hoerold, D., et al. (2012). A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception. Hum. Brain Mapp. 33, 1202-1211. doi: 10.1002/hbm.21281.
127. Okumura, T., Okochi, T., Kishi, T., Ikeda, M., Kitajima, T., Yamanouchi, Y., et al. (2009). No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. Neuromolecular Med. 11, 123-127. doi: 10.1007/s12017-009-8068-z.
128. Oldreive, C. E., Gaynor, S., and Doherty, G. H. (2008). Developmental changes in the response of murine cerebellar granule cells to nitric oxide. Neurochem. Int. 52, 1394-1401. doi: 10.1016/j.neuint.2008.02.010.
129. Oldreive, C. E., Gaynor, S., and Doherty, G. H. (2012). Effects of nitric oxide on the survival and neuritogenesis of cerebellar Purkinje neurons. J. Mol. Neurosci. 46, 336-342. doi: 10.1007/s12031-011-9590-7.
130. Owe-Larsson, B., Ekdahl, K., Edbom, T., Osby, U., Karlsson, H., Lundberg, C., et al. (2011). Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1117-1121. doi: 10.1016/j.pnpbp.2011.03.012.
131. Oya, K., Kishi, T., and Iwata, N. (2014). Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum. Psychopharmacol. 29, 483-491. doi: 10.1002/hup.2426.
132. Pae, C. U., Paik, I. H., Lee, C., Lee, S. J., Kim, J. J., and Lee, C. U. (2004). Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 50, 54-56. doi: 10.1159/000077942.
133. Pålsson, E., Lowry, J., and Klamer, D. (2010). Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia. Psychopharmacology 212, 643-651. doi: 10.1007/s00213-010-1992-7.
134. Pazvantoglu, O., Selek, S., Okay, I. T., Sengul, C., Karabekiroglu, K., Dilbaz, N., et al. (2009). Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin. Neurosci. 63, 693-700. doi: 10.1111/j.1440-1819.2009.02015.x.
135. Pino, O., Guilera, G., Gómez-Benito, J., Najas-García, A., Rufián, S., and Rojo, E. (2014). Neurodevelopment or neurodegeneration: review of theories of schizophrenia. Actas Esp. Psiquiatr. 42, 185-195.
136. Polazzi, E., and Contestabile, A. (2006). Overactivation of LPS-stimulated microglial cells by co-cultured neurons or neuron-conditioned medium. J. Neuroimmunol. 172, 104-111. doi: 10.1016/j.jneuroim.2005.11.005.
137. Possel, H., Noack, H., Putzke, J., Wolf, G., and Sies, H. (2000). Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 32, 51-59. doi: 10.1002/1098-1136(200010)32:13.0.CO;2-4.
138. Puri, V., McQuillin, A., Thirumalai, S., Lawrence, J., Krasucki, R., Choudhury, K., et al. (2006). Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample. Biol. Psychiatry 59, 195-197. doi: 10.1016/j.biopsych.2005.08.015.
139. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991). Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288, 481-487. doi: 10.1016/0003-9861(91)90224-7.
140. Raffa, M., Atig, F., Mhalla, A., Kerkeni, A., and Mechri, A. (2011). Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 11:124. doi: 10.1186/1471-244X-11-124.
141. Raffa, M., Barhoumi, S., Atig, F., Fendri, C., Kerkeni, A., and Mechri, A. (2012a). Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 371-375. doi: 10.1016/j.pnpbp.2012.07.013.
142. Raffa, M., Fendri, C., Ben Othmen, L., Slama, H., Amri, M., Kerkeni, A., et al. (2012b). The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 52-56. doi: 10.1016/j.pnpbp.2012.05.005.
143. Raffa, M., Mechri, A., Othman, L. B., Fendri, C., Gaha, L., and Kerkeni, A. (2009). Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1178-1183. doi: 10.1016/j.pnpbp.2009.06.018.
144. Ramirez, J., Garnica, R., Boll, M. C., Montes, S., and Rios, C. (2004). Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr. Res. 68, 357-361. doi: 10.1016/S0920-9964(03)00070-7.
145. Reddy, R. (2011). Antioxidant therapeutics for schizophrenia. Antioxid. Redox Signal. 15, 2047-2055. doi: 10.1089/ars.2010.3571.
146. Reddy, R., Keshavan, M., and Yao, J. K. (2003). Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 62, 205-212. doi: 10.1016/S0920-9964(02)00407-3.
147. Reif, A., Herterich, S., Strobel, A., Ehlis, A. C., Saur, D., Jacob, C. P., et al. (2006). A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol. Psychiatry 11, 286-300. doi: 10.1038/sj.mp.4001779.
148. Reif, A., Schecklmann, M., Eirich, E., Jacob, C. P., Jarczok, T. A., Kittel-Schneider, S., et al. (2011). A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia. Int. J. Neuropsychopharmacol. 14, 887-897. doi: 10.1017/S1461145710001677.
149. Ribeiro, B. M., do Carmo, M. R., Freire, R. S., Rocha, N. F., Borella, V. C., de Menezes, A. T., et al. (2013). Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr. Res. 151, 12-19. doi: 10.1016/j.schres.2013.10.040.
150. Ridnour, L. A., Thomas, D. D., Mancardi, D., Espey, M. G., Miranda, K. M., Paolocci, N., et al. (2004). The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol. Chem. 385, 1-10. doi: 10.1515/BC.2004.001.
151. Riley, B., Thiselton, D., Maher, B. S., Bigdeli, T., Wormley, B., McMichael, G. O., et al. (2010). Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol. Psychiatry 15, 29-37. doi: 10.1038/mp.2009.109.
152. Rimol, L. M., Hartberg, C. B., Nesvåg, R., Fennema-Notestine, C., Hagler, D. J. Jr. Pung, C. J., et al. (2010). Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol. Psychiatry 68, 41-50. doi: 10.1016/j.biopsych.2010.03.036.
153. Rodrigues, R., Petersen, R. B., and Perry, G. (2014). Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability. Cell. Mol. Neurobiol. 34, 925-949. doi: 10.1007/s10571-014-0074-5.
154. Rose, E. J., Greene, C., Kelly, S., Morris, D. W., Robertson, I. H., Fahey, C., et al. (2012). The NOS1 variant rs6490121 is associated with variation in prefrontal function and grey matter density in healthy individuals. Neuroimage 60, 614-622. doi: 10.1016/j.neuroimage.2011.12.054.
155. Rosen, Y., Reznik, I., Sluvis, A., Kaplan, D., and Mester, R. (2003). The significance of the nitric oxide in electro-convulsive therapy: a proposed neurophysiological mechanism. Med. Hypotheses 60, 424-429. doi: 10.1016/S0306-9877(02)00419-X.
156. Ryan, M. C., Sharifi, N., Condren, R., and Thakore, J. H. (2004). Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29, 1065-1070. doi: 10.1016/j.psyneuen.2003.08.011.
157. Scatton, B., Worms, P., Lloyd, K. G., and Bartholini, G. (1982). Cortical modulation of striatal function. Brain Res. 232, 331-343. doi: 10.1016/0006-8993(82)90277-3.
158. Seddon, M., Shah, A. M., and Casadei, B. (2007). Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc. Res. 75, 315-326. doi: 10.1016/j.cardiores.2007.04.031.
159. Shinkai, T., Ohmori, O., Hori, H., and Nakamura, J. (2002). Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol. Psychiatry 7, 560-563. doi: 10.1038/sj.mp.4001041.
160. Silberberg, G., Ben-Shachar, D., and Navon, R. (2010). Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 1318-1328. doi: 10.1002/ajmg.b.31112.
161. Sleiman, P., Wang, D., Glessner, J., Hadley, D., Gur, R. E., Cohen, N., et al. (2013). GWAS meta analysis identifies TSNARE1 as a novel Schizophrenia/Bipolar susceptibility locus. Sci. Rep. 3:3075. doi: 10.1038/srep03075.
162. Smith, C. V. (1992). "Free radical mechanisms of tissue injury" in Free Radical Mechanisms of Tissue Injury, eds M. T. Moslen and C. V. Smith (Boca Raton, FL: CRC Press), 1-22.
163. Song, X., Fan, X., Song, X., Zhang, J., Zhang, W., Li, X., et al. (2013). Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr. Res. 150, 269-273. doi: 10.1016/j.schres.2013.07.044.
164. Srivastava, N., Barthwal, M. K., Dalal, P. K., Agarwal, A. K., Nag, D., Srimal, R. C., et al. (2001). Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl.) 158, 140-145. doi: 10.1007/s002130100860.
165. Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., et al. (2009). Common variants conferring risk of schizophrenia. Nature 460, 744-747. doi: 10.1038/nature08186.
166. Suboticanec, K., Folnegoviæ-Smalc, V., Korbar, M., Mestroviæ, B., and Buzina, R. (1990). Vitamin C status in chronic schizophrenia. Biol. Psychiatry 28, 959-966. doi: 10.1016/0006-3223(90)90061-6.
167. Sullivan, P. F., Kendler, K. S., and Neale, M. C. (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60, 1187-1192. doi: 10.1001/archpsyc.60.12.1187.
168. Sunico, C. R., Portillo, F., González-Forero, D., and Moreno-López, B. (2005). Nitric-oxide-directed synaptic remodeling in the adult mammal CNS. J. Neurosci. 25, 1448-1458. doi: 10.1523/JNEUROSCI.4600-04.2005.
169. Szabadits, E., Cserép, C., Szonyi, A., Fukazawa, Y., Shigemoto, R., Watanabe, M., et al. (2011). NMDA receptors in hippocampal GABAergic synapses and their role in nitric oxide signaling. J. Neurosci. 31, 5893-5904 doi: 10.1523/JNEUROSCI.5938-10.2011.
170. Tanda, K., Nishi, A., Matsuo, N., Nakanishi, K., Yamasaki, N., Sugimoto, T., et al. (2009). Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain 2:19. doi: 10.1186/1756-6606-2-19.
171. Tandon, R., Keshavan, M. S., and Nasrallah, H. A. (2008). Schizophrenia, "just the facts": what we know in part 1: overview. Schizophr. Res. 100, 4-19. doi: 10.1016/j.schres.2008.01.022.
172. Tang, W., Huang, K., Tang, R., Zhou, G., Fang, C., Zhang, J., et al. (2008). Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. Int. J. Neuropsychopharmacol. 11, 1063-1071. doi: 10.1017/S1461145708008924.
173. Tarazi, F. I., Zhang, K., and Baldessarini, R. J. (2002). Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 7, 297-300. doi: 10.1016/S1089-8603(02)00126-X.
174. Tien, A. Y., and Eaton, W. W. (1992). Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch. Gen. Psychiatry 49, 37-46. doi: 10.1001/archpsyc.1992.01820010037005.
175. Timms, A. E., Dorschner, M. O., Wechsler, J., Choi, K. Y., Kirkwood, R., Girirajan, S., et al. (2013). Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 70, 582-590. doi: 10.1001/jamapsychiatry.2013.1195.
176. Toda, N. (2012). Age-related changes in endothelial function and blood flow regulation. Pharmacol. Ther. 133, 159-176. doi: 10.1016/j.pharmthera.2011.10.004.
177. Toda, N., Ayajiki, K., and Okamura, T. (2009). Cerebral blood flow regulation by nitric oxide in neurological disorders. Can. J. Physiol. Pharmacol. 87, 581-594. doi: 10.1139/Y09-048.
178. Tohgi, H., Abe, T., Yamazaki, K., Murata, T., Isobe, C., and Ishizaki, E. (1998). The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type. J. Neural Transm. 105, 1283-1291. doi: 10.1007/s007020050131.
179. Tsai, M. C., Liou, C. W., Lin, T. K., Lin, I. M., and Huang, T. L. (2013). Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. Psychiatry Res. 209, 284-290. doi: 10.1016/j.psychres.2013.01.023.
180. Upreti, C., Zhang, X. L., Alford, S., and Stanton, P. K. (2013). Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release. Neuropharmacology 66, 31-39. doi: 10.1016/j.neuropharm.2012.05.004.
181. Uranova, N. A., Vostrikov, V. M., Orlovskaya, D. D., and Rachmanova, V. I. (2004). Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67, 269-275. doi: 10.1016/S0920-9964(03)00181-6.
182. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., and Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44-84. doi: 10.1016/j.biocel.2006.07.001.
183. van Rossum, J. M. (1966). The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160, 492-494.
184. Vasankari, T., Kujala, U., Heinonen, O., Kapanen, J., and Ahotupa, M. (1995). Measurement of serum lipid peroxidation during exercise using three different methods: diene conjugation, thiobarbituric acid reactive material and fluorescent chromolipids. Clin. Chim. Acta 234, 63-69. doi: 10.1016/0009-8981(94)05976-Y.
185. Virarkar, M., Alappat, L., Bradford, P. G., and Awad, A. B. (2013). L-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit. Rev. Food Sci. Nutr. 53, 1157-1167. doi: 10.1080/10408398.2011.573885.
186. Vleeming, W., Rambali, B., and Opperhuizen, A. (2002). The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob. Res. 4, 341-348. doi: 10.1080/14622200210142724.
187. Wang, H. H., Hsieh, H. L., and Yang, C. M. (2011). Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9. J. Cell. Physiol. 226, 2244-2256. doi: 10.1002/jcp.22560.
188. Wang, J., Ma, X. H., Xiang, B., Wu, J. Y., Wang, Y. C., Deng, W., et al. (2012). [Association study of NOS1 gene polymorphisms and schizophrenia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 29, 459-463. doi: 10.3760/cma.j.issn.1003-9406.2012.04.018.
189. Wass, C., Klamer, D., Katsarogiannis, E., Pålsson, E., Svensson, L., Fejgin, K., et al. (2011). L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. BMC Med. 9:40. doi: 10.1186/1741-7015-9-40.
190. Wass, C., Svensson, L., Fejgin, K., Pålsson, E., Archer, T., Engel, J. A., et al. (2008). Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. Pharmacol. Biochem. Behav. 89, 352-359. doi: 10.1016/j.pbb.2008.01.011.
191. Wayner, D. D., Burton, G. W., Ingold, K. U., Barclay, L. R., and Locke, S. J. (1987). The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta 924, 408-419. doi: 10.1016/0304-4165(87)90155-3.
192. Weber, H., Klamer, D., Freudenberg, F., Kittel-Schneider, S., Rivero, O., Scholz, C. J., et al. (2014). The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia: further evidence and meta-analysis. Eur. Neuropsychopharmacol. 24, 65-85. doi: 10.1016/j.euroneuro.2013.09.005.
193. White, M. F., Gazzola, G. C., and Christensen, H. N. (1982). Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J. Biol. Chem. 257, 4443-4449.
194. Wratten, N. S., Memoli, H., Huang, Y., Dulencin, A. M., Matteson, P. G., Cornacchia, M. A., et al. (2009). Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am. J. Psychiatry 166, 434-441. doi: 10.1176/appi.ajp.2008.08081266.
195. Wu, J. Q., Chen da, C., Tan, Y. L., Tan, S., Wang, Z., Yang, F., et al. (2014). Association of altered CuZn superoxide dismutase and cognitive impairment in schizophrenia patients with tardive dyskinesia. J. Psychiatr. Res. 58, 167-174. doi: 10.1016/j.jpsychires.2014.07.028.
196. Wu, J. Q., Kosten, T. R., and Zhang, X. Y. (2013). Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 46, 200-206. doi: 10.1016/j.pnpbp.2013.02.015.
197. Wu, Z., Zhang, X. Y., Wang, H., Tang, W., Xia, Y., Zhang, F., et al. (2012). Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 34-38. doi: 10.1016/j.pnpbp.2011.08.018.
198. Xia, Y., Tsai, A. L., Berka, V., and Zweier, J. L. (1998). Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 273, 25804-25808. doi: 10.1074/jbc.273.40.25804.
199. Xing, G., Chavko, M., Zhang, L. X., Yang, S., and Post, R. M. (2002). Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr. Res. 58, 21-30. doi: 10.1016/S0920-9964(01)00388-7.
200. Xu, B., Wratten, N., Charych, E. I., Buyske, S., Firestein, B. L., and Brzustowicz, L. M. (2005). Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2:e263. doi: 10.1371/journal.pmed.0020263.
201. Yao, J. K., Condray, R., Dougherty, G. G. Jr. Keshavan, M. S., Montrose, D. M., Matson, W. R., et al. (2012). Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS ONE 7:e42165. doi: 10.1371/journal.pone.0042165.
202. Yao, J. K., and Keshavan, M. S. (2011). Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal. 15, 2011-2035. doi: 10.1089/ars.2010.3603.
203. Yao, J. K., Leonard, S., and Reddy, R. D. (2004). Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr. Bull. 30, 923-934. doi: 10.1093/oxfordjournals.schbul.a007142.
204. Yao, J. K., Reddy, R., and van Kammen, D. P. (1998). Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 80, 29-39. doi: 10.1016/S0165-1781(98)00051-1.
205. Yao, J. K., Reddy, R., and van Kammen, D. P. (2000). Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 97, 137-151. doi: 10.1016/S0165-1781(00)00230-4.
206. Yilmaz, N., Herken, H., Cicek, H. K., Celik, A., Yürekli, M., and Akyol, O. (2007). Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med. Princ. Pract. 16, 137-141. doi: 10.1159/000098367.
207. Zeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M., and Akhondzadeh, S. (2014). L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J. Psychiatr. Res. 59, 125-131. doi: 10.1016/j.jpsychires.2014.08.016.
208. Zhang, M., Zhao, Z., He, L., and Wan, C. (2010). A meta-analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 53, 112-124. doi: 10.1007/s11427-010-0013-8.
209. Zhang, X. R., Wang, Y. X., Zhang, Z. J., Li, L., and Reynolds, G. P. (2012). The effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine D2 receptor in the male rat. PLoS ONE 7:e33247. doi: 10.1371/journal.pone.0033247.
210. Zhang, X. Y., Chen da, C., Xiu, M. H., Wang, F., Qi, L. Y., Sun, H. Q., et al. (2009). The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr. Res. 113, 151-157. doi: 10.1016/j.schres.2009.05.016.
211. Zhang, X. Y., Chen da, C., Xiu, M. H., Yang, F. D., Tan, Y. L., He, S., et al. (2013). Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr. Res. 143, 301-306. doi: 10.1016/j.schres.2012.11.017.
212. Zhang, X. Y., Tan, Y. L., Cao, L. Y., Wu, G. Y., Xu, Q., Shen, Y., et al. (2006). Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 81, 291-300. doi: 10.1016/j.schres.2005.10.011.
213. Zhou, L., and Zhu, D. Y. (2009). Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 20, 223-230. doi: 10.1016/j.niox.2009.03.001.
214. Zhou, Y., Zhou, L., Chen, H., and Koliatsos, V. E. (2006). An AMPA glutamatergic receptor activation-nitric oxide synthesis step signals transsynaptic apoptosis in limbic cortex. Neuropharmacology 51, 67-76. doi: 10.1016/j.neuropharm.2006.03.002.